94 related articles for article (PubMed ID: 11032927)
1. Antitumor effects of fotemustine and busulfan against a human neuroblastoma xenograft.
Ikeda H; Tsuchida Y; Wu J; Suzuki N; Kuroiwa M; Choi SH; Morikawa A
Oncol Rep; 2000; 7(6):1265-8. PubMed ID: 11032927
[TBL] [Abstract][Full Text] [Related]
2. Activity of fotemustine in medulloblastoma and malignant glioma xenografts in relation to O6-alkylguanine-DNA alkyltransferase and alkylpurine-DNA N-glycosylase activity.
Vassal G; Boland I; Terrier-Lacombe MJ; Watson AJ; Margison GP; Vénuat AM; Morizet J; Parker F; Lacroix C; Lellouch-Tubiana A; Pierre-Kahn A; Poullain MG; Gouyette A
Clin Cancer Res; 1998 Feb; 4(2):463-8. PubMed ID: 9516937
[TBL] [Abstract][Full Text] [Related]
3. Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
Némati F; de Montrion C; Lang G; Kraus-Berthier L; Carita G; Sastre-Garau X; Berniard A; Vallerand D; Geneste O; de Plater L; Pierré A; Lockhart B; Desjardins L; Piperno-Neumann S; Depil S; Decaudin D
PLoS One; 2014; 9(1):e80836. PubMed ID: 24454684
[TBL] [Abstract][Full Text] [Related]
4. Viability of a human melanoma cell after single and combined treatment with fotemustine, dacarbazine, and proton irradiation.
Petrović IM; Korićanac LB; Todorović DV; Ristić-Fira AM; Valastro LM; Privitera G; Cuttone G
Ann N Y Acad Sci; 2007 Jan; 1095():154-64. PubMed ID: 17404028
[TBL] [Abstract][Full Text] [Related]
5. Continuous versus intermittent administration of human endostatin in xenografted human neuroblastoma.
Kuroiwa M; Takeuchi T; Lee JH; Yoshizawa J; Hirato J; Kaneko S; Choi SH; Suzuki N; Ikeda H; Tsuchida Y
J Pediatr Surg; 2003 Oct; 38(10):1499-505. PubMed ID: 14577075
[TBL] [Abstract][Full Text] [Related]
6. Effects of recombinant human endostatin on a human neuroblastoma xenograft.
Kuroiwa M; Ikeda H; Hongo T; Tsuchida Y; Hirato J; Kaneko Y; Suzuki N; Obana K; Makino SI
Int J Mol Med; 2001 Oct; 8(4):391-6. PubMed ID: 11562777
[TBL] [Abstract][Full Text] [Related]
7. Effects of cyclophosphamide, cis-platinum, nitrosourea (ACNU), melphalan, and dacarbazine on a cytogenetically highly malignant neuroblastoma xenograft.
Makino S; Tsuchida Y; Nakajo T; Kanda N; Kaneko Y
Med Pediatr Oncol; 1986; 14(1):36-40. PubMed ID: 2419742
[TBL] [Abstract][Full Text] [Related]
8. Pharmacology of EAPB0203, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral activity on melanoma.
Khier S; Deleuze-Masquéfa C; Moarbess G; Gattacceca F; Margout D; Solassol I; Cooper JF; Pinguet F; Bonnet PA; Bressolle FM
Eur J Pharm Sci; 2010 Jan; 39(1-3):23-9. PubMed ID: 19854270
[TBL] [Abstract][Full Text] [Related]
9. Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations.
Boland I; Vassal G; Morizet J; Terrier-Lacombe MJ; Valteau-Couanet D; Kalifa C; Hartmann O; Gouyette A
Br J Cancer; 1999 Feb; 79(5-6):787-92. PubMed ID: 10070870
[TBL] [Abstract][Full Text] [Related]
10. Effects of newly introduced chemotherapeutic agents on a cytogenetically highly malignant neuroblastoma, xenotransplanted in nude mice.
Makino S; Kashii A; Kanazawa K; Tsuchida Y
J Pediatr Surg; 1993 Apr; 28(4):612-6. PubMed ID: 8483078
[TBL] [Abstract][Full Text] [Related]
11. Cytotoxicity and DNA damaging effects of a new nitrosourea, fotemustine, diethyl- 1-(3-(2-chloroethyl)-3-nitrosoureido) ethylphosphonate-S10036.
Tapiero H; Yin MB; Catalin J; Paraire M; Deloffre P; Rustum Y; Bizzari JP; Tew KD
Anticancer Res; 1989; 9(6):1617-22. PubMed ID: 2627116
[TBL] [Abstract][Full Text] [Related]
12. Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes.
Boutin JA; Norbeck K; Moldeus P; Genton A; Paraire M; Bizzari JP; Lavielle G; Cudennec CA
Eur J Cancer Clin Oncol; 1989 Sep; 25(9):1311-6. PubMed ID: 2806354
[TBL] [Abstract][Full Text] [Related]
13. Cytochrome-P450 induction and antineoplastic action of fotemustine in mice.
Isa M; Cumps J; Poupaert JH; Atassi G
J Pharm Belg; 1996; 51(4):192-4. PubMed ID: 8965249
[No Abstract] [Full Text] [Related]
14. [DNA damage induced by fotemustine in cultured HL60 cells].
Shou J; Feng XW
Zhongguo Yao Li Xue Bao; 1996 Sep; 17(5):474-7. PubMed ID: 9863179
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of fotemustine in pediatric patients with refractory brain tumors.
Hargrave DR; Bouffet E; Gammon J; Tariq N; Grant RM; Baruchel S
Cancer; 2002 Sep; 95(6):1294-301. PubMed ID: 12216098
[TBL] [Abstract][Full Text] [Related]
16. B-Raf inhibitor vemurafenib in combination with temozolomide and fotemustine in the killing response of malignant melanoma cells.
Roos WP; Quiros S; Krumm A; Merz S; Switzeny OJ; Christmann M; Loquai C; Kaina B
Oncotarget; 2014 Dec; 5(24):12607-20. PubMed ID: 25557167
[TBL] [Abstract][Full Text] [Related]
17. Fotemustine in the treatment of brain primary tumors and metastases.
Khayat D; Giroux B; Berille J; Cour V; Gerard B; Sarkany M; Bertrand P; Bizzari JP
Cancer Invest; 1994; 12(4):414-20. PubMed ID: 8032964
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines.
Fischel JL; Barbé V; Berlion M; Formento P; Berrile J; Bizzari JP; Milano G
Eur J Cancer; 1993; 29A(16):2269-73. PubMed ID: 8110498
[TBL] [Abstract][Full Text] [Related]
19. In vitro chemosensitivity testing of Fotemustine (S 10036), a new antitumor nitrosourea.
Fischel JL; Formento P; Etienne MC; Gioanni J; Frenay M; Deloffre P; Bizzari JP; Milano G
Cancer Chemother Pharmacol; 1990; 25(5):337-41. PubMed ID: 2306793
[TBL] [Abstract][Full Text] [Related]
20. The translesion polymerase Rev3L in the tolerance of alkylating anticancer drugs.
Roos WP; Tsaalbi-Shtylik A; Tsaryk R; Güvercin F; de Wind N; Kaina B
Mol Pharmacol; 2009 Oct; 76(4):927-34. PubMed ID: 19641035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
